| Today’s Big NewsMar 7, 2025 |
| By Nick Paul Taylor Johnson & Johnson has added to the opioid kappa blues. Months after Neumora reported a phase 3 flop, J&J has stopped development of its rival drug candidate aticaprant as an adjunctive treatment for major depressive disorder. |
|
|
|
By Nick Paul Taylor Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical data and their pipeline priorities. |
By Gabrielle Masson In defiance of federal orders, the National Institutes of Health is still terminating grants to researchers across the country, The Boston Globe reports. |
By Zoey Becker The newest executive to join the ranks at Pfizer is ten-year Johnson & Johnson vet James List, M.D., Ph.D. At Pfizer, he'll be responsible for leading the company’s pipeline of cardiovascular, metabolic, hematologic, and obesity medicines from early discovery to late development. |
|
Tuesday, March 11, 2025 | 11am ET / 8am PT In the world of clinical trials, where precision and compliance are critical, the role of technology is more important than ever. Join us to learn how to harness the latest innovations for driving efficiencies and more streamlined experiences for patients. Register now to take a deep dive into the most pressing challenges in clinical trials today!
|
|
By James Waldron Atea Pharmaceuticals has laid off a quarter of its workforce so far this year as the biotech prepares to launch a phase 3 trial of its hepatitis C cocktail. |
By Darren Incorvaia,Zoey Becker Sage Chief Medical Officer Laura Gault, M.D., Ph.D., is stepping down to pursue a new opportunity effective March 21, the latest change for a company that has had a recent string of clinical failures. |
By Ben Adams Theriva Biologics is putting more of its eggs in the VCN-01 basket as it unveils a change up in its R&D focus. |
By James Waldron Arcturus believes it’s “highly unlikely” it will lose the government funding for its mRNA bird flu vaccine trial, despite rumors swirling that Moderna’s funding will be revoked. |
By James Waldron Roche and its Genentech subsidiary are planning to hitch up their cardiovascular, renal and metabolism R&D work and shift it over to a new center in Harvard’s Enterprise Research Campus. |
By Andrea Park,Gabrielle Masson This week on "The Top Line," we dig into several of the biggest private funding rounds in biotech last year and discuss the shifting VC landscape. |
By Zoey Becker If confirmed, Johns Hopkins surgeon Martin Makary, M.D., would take the reins at the FDA as the agency undergoes cost-cutting measures from the Trump administration. |
By Paige Minemyer The confirmation follows weeks of speculation and rumors that Sycamore was planning to take over Walgreens and take the company private. |
By Angus Liu U.S. President Donald Trump has issued a memorandum directing federal agencies to restrict inbound and outbound investments related to China in several sectors, including biotech. Pfizer could shift overseas production to the U.S. if tariffs become a problem, CEO Albert Bourla said. Blackstone bought a 60% stake in Japanese CRO giant CMIC. And more. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we dig into several of the biggest private funding rounds in biotech last year and discuss the shifting VC landscape. |
|
|---|
|
|
|
Thursday, March 20, 2025 | 11am ET / 8am PT AI is no longer a novelty—it's an expectation. As stakeholders demand evidence of real-world impact, the focus is shifting from the tools themselves to the tangible results they deliver. Join us to explore how predictive sales intelligence and omnichannel strategies are transforming HCP engagement. Register now.
|
|
| WhitepaperRead about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperDiscover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
| WhitepaperDevelop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| |
|
